Paper Details

  1. Home
  2. Paper Details

IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.

Author: ChenBingliang, JingHua, KuangZhihui, LiLi, LiuJunjian, LiuYang, QiuXuan, SunTa, WangLi, WuDongdong, WuMin, WuWeiwei, WuYue, WuZhihai, YiShuai, ZhouShuaixiang

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

IBI112, a potent anti-IL-23 monoclonal antibody under clinical development, effectively neutralized IL-23, blocked IL-17 production, and alleviated disease symptoms in two mouse models of psoriasis. This extended half-life antibody shows promise as a treatment for psoriasis.
Paper Details　
Original Abstract of the Article :
Psoriasis is a highly prevalent inflammatory skin disease. Plaque psoriasis is the most common type of psoriasis, and the interleukin (IL)-23/IL-17 axis plays a key role in disease progression. In this article, we describe IBI112, a highly potent anti-IL-23 monoclonal antibody under clinical develop...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.intimp.2020.107008

データ提供：米国国立医学図書館（NLM）

Psoriasis: A Desert Storm on Your Skin

Psoriasis, a chronic inflammatory skin condition, can be a significant challenge for those affected. This study investigates the potential of IBI112, a monoclonal antibody targeting a specific protein involved in psoriasis development, as a novel treatment. Imagine IBI112 as a desert shield protecting your skin from the onslaught of inflammatory storms. Researchers evaluated IBI112's effectiveness in preclinical models of psoriasis, demonstrating its ability to suppress inflammation and alleviate disease symptoms.

A New Shield for Psoriasis

The study found that IBI112 effectively reduced skin inflammation and improved disease severity in psoriasis models. These promising results highlight the potential of IBI112 as a novel treatment option for psoriasis.

Managing Psoriasis

If you suffer from psoriasis, it's crucial to consult with a dermatologist to explore available treatment options, which may include topical medications, phototherapy, systemic medications, and biologic therapies like IBI112.

Dr.Camel's Conclusion

Psoriasis, like a relentless desert sandstorm, can leave your skin feeling raw and irritated. This study offers a glimmer of hope, suggesting that IBI112 could provide a new shield to protect your skin from the harsh realities of psoriasis.

Date :
  1. Date Completed 2021-05-25
  2. Date Revised 2021-05-25
Further Info :

Pubmed ID

33069927

DOI: Digital Object Identifier

10.1016/j.intimp.2020.107008

Related Literature

Article Analysis
・Effects of guselkumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.